Schizophrenia Research
Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.
Schizophrenia Research Products Targets
- Others (13)
- Sigma2 Receptor (4)
- Sigma1 Receptor (16)
- D4 Receptor (12)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- GPR55 (8)
- CB2 Receptor (6)
- CB1 Receptor (17)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- D3 Receptor (12)
- NK3 Receptor (5)
- Carboxypeptidase (1)
- NMDA Receptor (87)
- Kainate Receptor (22)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trace Amine 1 Receptor (2)
- Glutamate Transporter (18)
- Histamine H3 Receptor (22)
- Neurotensin Receptor (7)
- Monoamine Oxidase (10)
- iNOS (11)
- M5 Receptor (2)
- M4 Receptor (3)
- M3 Receptor (4)
- M2 Receptor (5)
- M1 Receptor (8)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Protein serine and threonine phosphatase (16)
- Protein Arginine Methyltransferase (2)
- Phosphodiesterase (34)
Products for Schizophrenia Research - Page 65
- Cat.No. Product Name Information/Activity
-
BCC7922
Ro 01-6128
302841-86-7
-
BCC7921
Ro 67-4853
302841-89-0
-
BCC6145
Ro 67-7476
Ro 67-7476 is a positive allosteric modulator of mGlu1 receptors.
-
BCC6154
VU 0285683
327056-22-4
-
BCC4595
VU 0357121
VU0357121 is a novel positive and highly selective allosteric modulator (PAM) of mGlu5R with EC50 of 33 nM.
-
BCC6141
VU 0360172 hydrochloride
1309976-62-2
-
BCC6159
VU 0360223
1274859-33-4
-
BCC7649
VU 1545
890764-63-3
-
BCC7936
VU 29
890764-36-0
-
BCC6969
(2R,4R)-APDC
(2R,4R)-APDC is a selective group II metabotropic glutamate receptors (mGluRs) agonist. (2R,4R)-APDC has anticonvulsant and neuroprotective effects.


